back to school

University of Houston, Intel team up to prepare workforce for AI revolution

UH's business school has a new program focused on artificial intelligence thanks to a partnership with Intel. Photo via uh.edu

The University of Houston’s C.T. Bauer College of Business has teamed up with semiconductor chip manufacturer Intel Corp. to provide training in artificial intelligence.

The new artificial intelligence program features a standalone business certificate with two specialized courses; the first course launched in January. Bauer also plans to offer non-degree certificate programs in AI, such as the AI Certificate for Entrepreneurship and AI Certificate for Executive Education.

In a news release, Elizabeth McGee, chief strategy and innovation adviser at Santa Clara, California-based Intel, says the UH initiative will help bridge the AI knowledge gap. An online search indicates hundreds of AI-related jobs are open in the Houston area.

“Digital upskilling, or digital readiness, needs to be a catapult for economic prosperity for everyone and not a dividing point,” McGee says. “I commend the University of Houston for being the first higher education institution to take our award-winning curriculum and lend your expertise in entrepreneurship, your access to the broader Houston community, and supporting this digital upskilling for everyone.”

AI education has taken on a greater sense of urgency as the healthcare and energy sectors, among others, incorporate AI into their operations.

Paul Pavlou, dean of the Bauer College and Cullen Distinguished Chair Professor, says the collaboration between UH and Intel will help propel growth and innovation in Houston’s tech sector. Intel, whose only Texas location is in Austin, is a key player in the expanding AI market.

“Intel has been very generous with their resources, and with our expertise in analytics and faculty research and students’ initiative in bringing new products to life, the opportunities for this collaboration to be transformative are endless,” Pavlou says.

AI is growing at an incredibly rapid pace. According to Precedence Research, the size of the global AI market was estimated at $119.78 billion in 2022 and is expected to reach nearly $1.6 trillion by 2030.

“While some markets, sectors and individual businesses are more advanced than others, AI is still at a very early stage of development overall,” says professional services firm PwC. “From a macroeconomic point of view, there are … opportunities for emerging markets to leapfrog more developed counterparts.”

AI is viewed as both positive and negative in terms of today’s workforce.

“AI is a fast-evolving technology with great potential to make workers more productive, to make firms more efficient, and to spur innovations in new products and services. At the same time, AI can also be used to automate existing jobs and exacerbate inequality, and it can lead to discrimination against workers,” says a report published by the White House in 2022.

Houston Mayor Sylvester Turner and Houston City Council celebrated “AI Innovation and Entrepreneurship Day” at City Hall on Feb. 7. Photo via Facebook

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted